Methods of medical visualization and thermal ablation as a new approach to treatment of hyperparathyroidism

Abstract

The pathologies of parathyroid glands are widespread among endocrine system diseases, excluding diabetes and thyroid pathology. There are only two methods that are used to treat hyperparathyroidisms, such as surgery and conservative therapy. However, transracial thermal destruction methods (ablation) have recently appeared in clinical practice. The methods have good precision and connect with physical phenomena, such as interaction laser, radiofrequency, microwave, and HIFU irradiation with bio substance. The review is dedicated to critically analyze the modern methods for local thermal destruction of the hyper-functioning parathyroid glands. The review includes data from randomized clinical trials from 2012 to 2021. The studies were from Google Scholar and Pubmed with a total number of 1,938 patients (laser ablation ― 216 patients, radiofrequency ablation ― 225, microwave ablation ― 1467, high-density ultrasound ablation ― 30 patients). Recommendations methods of thermal destruction application were obtained during the review. Furthermore, we have designed some algorithms for hyperparathyroidism treatment. Moreover, thermal destruction methods were observed. There are four modern methods of thermal destruction which have been analyzed like alternatives to surgery. Each of them has advantages and disadvantages, its profile of safety and effectiveness. After processing information from a proven database, the most popular among specialists is methods of microwave ablation. However, laser ablation is more effective than other ways.

Keywords

hyperparathyroidism / thermal destruction / ablation of parathyroid glands / laser ablation / radiofrequency ablation / microwave ablation / HIFU ablation

References

[1] Fraser WD. Hyperparathyroidism. Lancet. 2009;374(9684): 145–158. doi: 10.1016/S0140-6736(09)60507-9

[2] Fraser W.D. Hyperparathyroidism//Lancet. 2009. Vol. 374, N 9684. P. 145–158. doi: 10.1016/S0140-6736(09)60507-9

[3] Vadiveloo T, Donnan PT, Leese GP. A population-based study of the epidemiology of chronic hypoparathyroidism. J Bone Miner Res. 2018;33(3):478–485. doi: 10.1002/jbmr.3329

[4] Vadiveloo T., Donnan P.T., Leese G.P. A population-based study of the epidemiology of chronic hypoparathyroidism//J Bone Miner Res. 2018. Vol. 33, N 3. Р. 478–485. doi: 10.1002/jbmr.3329

[5] Yanevskaya LG, Karonova TL, Sleptsov IV, et al. Primary hyperparathyroidism: clinical forms and their features. Retrospective study. Clinical and Experimental Thyroidology. 2019;15(1):19–29. (In Russ). doi: 10.14341/ket10213

[6] Яневская Л.Г., Каронова Т.Л., Слепцов И.В., и др. Первичный гиперпаратиреоз: клинические формы и их особенности. Результаты ретроспективного исследования//Клиническая и экспериментальная тиреоидология. 2019. T. 15, № 1. C. 19–29. doi: 10.14341/ket10213

[7] Mokrysheva NG, Eremkina AK, Mirnaya SS, et al. Challenges in differential diagnosis between primary and secondary forms of hyperparathyroidism. Obesity and Metabolism. 2017;14(3):48–53. (In Russ). doi: 10.14341/omet2017348-53

[8] Мокрышева Н.Г., Еремкина А.К., Мирная С.С., Ковалева Е.В. Трудности дифференциальной диагностики между первичной и вторичной формами гиперпаратиреоза//Ожирение и метаболизм. 2017. T. 14, № 3. C. 48–53. doi: 10.14341/omet2017348-53

[9] Smorshchok VN, Kuznetsov NS, Artemova AM, et al. Surgical treatment of patients with secondary hyperparathyroidism in chronic renal failure. Problems of Endocrinology. 2003;49(6):36–41. (In Russ). doi: 10.14341/probl11761

[10] Сморщок В.Н., Кузнецов Н.С., Артемова А.М., и др. Xирургическое лечение больных с вторичным гиперпаратиреозом при хронической почечной недостаточности//Проблемы эндокринологии. 2003. Т. 49, № 6. С. 36–41. doi: 10.14341/probl11761

[11] Slashchuk KY, Degtyarev MV, Rumyantsev PO, et al. Imaging methods of the parathyroid glands in primary hyperparathyroidism. Literature review. Endocrine Surgery. 2019;13(4):153–174. (In Russ). doi: 10.14341/serg12241

[12] Слащук К.Ю., Дегтярев М.В., Румянцев П.О., и др. Методы визуализации околощитовидных желез при первичном гиперпаратиреозе. Обзор литературы//Эндокринная хирургия. 2019. T. 13, № 4. С. 153–174. doi: 10.14341/serg12241

[13] Broos WM, van der Zant FM, Knol JJ, Wondergem M. Choline PET/CT in parathyroid imaging: a systematic review. Nucl Med Commun. 2019;40(2):96–105. doi: 10.1097/MNM.0000000000000952

[14] Broos W.M., van der Zant F.M., Knol J.J., Wondergem M. Choline PET/CT in parathyroid imaging: a systematic review//Nucl Med Commun. 2019. Vol. 40, N 2. P. 96–105. doi: 10.1097/MNM.0000000000000952

[15] Yu N, Leese GP, Smith D, Donnan PT. The natural history of treated and untreated primary hyperparathyroidism: the parathyroid epidemiology and audit research study. QJM. 2011;104(6):513–521. doi: 10.1093/qjmed/hcq261

[16] Yu N., Leese G.P., Smith D., Donnan P.T. The natural history of treated and untreated primary hyperparathyroidism: the parathyroid epidemiology and audit research study//QJM. 2011. Vol. 104, N 6. P. 513–521. doi: 10.1093/qjmed/hcq261

[17] Ishii H, Stechman MJ, Watkinson JC, et al. A review of parathyroid surgery for primary hyperparathyroidism from the United Kingdom Registry of Endocrine and Thyroid Surgery (UKRETS). World J Surg. 2021;45:782–789. doi: 10.1007/s00268-020-05885-5

[18] Ishii H., Stechman M.J., Watkinson J.C., et al. A review of parathyroid surgery for primary hyperparathyroidism from the United Kingdom Registry of Endocrine and Thyroid Surgery (UKRETS)//World J Surg. 2021. Vol. 45. P. 782–789. doi: 10.1007/s00268-020-05885-5

[19] Kim MS, Kim GH, Lee CH, et al. Surgical outcomes of subtotal parathyroidectomy for renal hyperparathyroidism. Clin Exp Otorhinolaryngol. 2020;13(2):173–178. doi: 10.21053/ceo.2019.01340

[20] Kim M.S., Kim G.H., Lee C.H., et al. Surgical outcomes of subtotal parathyroidectomy for renal hyperparathyroidism//Clin Exp Otorhinolaryngol. 2020. Vol. 13, N 2. P. 173–178. doi: 10.21053/ceo.2019.01340

[21] LeBlanc RA, Isaac A, Abele J, et al. Validation of a novel method for localization of parathyroid adenomas using SPECT/CT. J Otolaryngol Head Neck Surg. 2018;47(1):65. doi: 10.1186/s40463-018-0307-6

[22] LeBlanc R.A., Isaac A., Abele J., et al. Validation of a novel method for localization of parathyroid adenomas using SPECT/CT//J Otolaryngol Head Neck Surg. 2018. Vol. 47, N 1. P. 65. doi: 10.1186/s40463-018-0307-6

[23] Zhao S, Guo X, Taniguchi M, et al. Detection of mediastinal lymph node metastases using indocyanine green (ICG) fluorescence imaging in an orthotopic implantation model. Anticancer Res. 2020;40(4):1875–1882. doi: 10.21873/anticanres.14141

[24] Zhao S., Guo X., Taniguchi M., et al. Detection of mediastinal lymph node metastases using indocyanine green (ICG) fluorescence imaging in an orthotopic implantation model//Anticancer Res. 2020. Vol. 40, N 4. P. 1875–1882. doi: 10.21873/anticanres.14141

[25] Kose E, Rudin AV, Kahramangil B, et al. Autofluorescence imaging of parathyroid glands: An assessment of potential indications. Surgery. 2020;167(1):173–179. doi: 10.1016/j.surg.2019.04.072

[26] Kose E., Rudin A.V., Kahramangil B., et al. Autofluorescence imaging of parathyroid glands: An assessment of potential indications//Surgery. 2020. Vol. 167, N 1. Р. 173–179. doi: 10.1016/j.surg.2019.04.072

[27] Wu B, Haigh PI, Hwang R, et al. Underutilization of parathyroidectomy in elderly patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2010;95(9):4324–4330. doi: 10.1210/jc.2009-2819

[28] Wu B., Haigh P.I., Hwang R., et al. Underutilization of parathyroidectomy in elderly patients with primary hyperparathyroidism//J Clin Endocrinol Metab. 2010. Vol. 95, N 9. Р. 4324–4330 doi: 10.1210/jc.2009-2819

[29] Kovatcheva RD, Vlahov JD, Stoinov JI, et al. High-intensity focused ultrasound (HIFU) treatment in uraemic secondary hyperparathyroidism. Nephrol Dial Transplant. 2012;27(1):76–80. doi: 10.1093/ndt/gfr590

[30] Kovatcheva R.D., Vlahov J.D., Stoinov J.I., et al. High-intensity focused ultrasound (HIFU) treatment in uraemic secondary hyperparathyroidism//Nephrol Dial Transplant. 2012. Vol. 27, N 1. P. 76–80. doi: 10.1093/ndt/gfr590

[31] Korkusuz H, Nimsdorf F, Happel C, et al. Percutaneous microwave ablation of benign thyroid nodules. Functional imaging in comparison to nodular volume reduction at a 3-month follow-up. Nuklearmedizin. 2015;54(1):13–19. doi: 10.3413/Nukmed-0678-14-06

[32] Korkusuz H., Nimsdorf F., Happel C., et al. Percutaneous microwave ablation of benign thyroid nodules. Functional imaging in comparison to nodular volume reduction at a 3-month follow-up//Nuklearmedizin. 2015. Vol. 54, N 1. P. 13–19. doi: 10.3413/Nukmed-0678-14-06

[33] Zeng Z, Peng CZ, Liu JB, et al. Efficacy of ultrasound-guided radiofrequency ablation of parathyroid hyperplasia: single session vs. two-session for effect on hypocalcemia. Sci Rep. 2020;10(1):6206. doi: 10.1038/s41598-020-63299-8

[34] Zeng Z., Peng C.Z., Liu J.B., et al. Efficacy of ultrasound-guided radiofrequency ablation of parathyroid hyperplasia: single session vs. two-session for effect on hypocalcemia//Sci Rep. 2020. Vol. 10, N 1. P. 6206. doi: 10.1038/s41598-020-63299-8

[35] Casara D, Rubello D, Piotto A, Pelizzo MR. 99mTc-MIBI radio-guided minimally invasive parathyroid surgery planned on the basis of a preoperative combined 99mTc-pertechnetate/99mTc-MIBI and ultrasound imaging protocol. Eur J Nucl Med. 2000;27(9):1300–1304. doi: 10.1007/s002590000297

[36] Casara D., Rubello D., Piotto A., Pelizzo M.R. 99mTc-MIBI radio-guided minimally invasive parathyroid surgery planned on the basis of a preoperative combined 99mTc-pertechnetate/99mTc-MIBI and ultrasound imaging protocol//Eur J Nucl Med. 2000. Vol. 27, N 9. P. 1300–1304. doi: 10.1007/s002590000297

[37] Huang Z, Lou C. 99mTcO4-/99mTc-MIBI dual-tracer scintigraphy for preoperative localization of parathyroid adenomas. J Int Med Res. 2019;47(2):836–845. doi: 10.1177/0300060518813742

[38] Huang Z., Lou C. 99mTcO4-/99mTc-MIBI dual-tracer scintigraphy for preoperative localization of parathyroid adenomas//J Int Med Res. 2019. Vol. 47, N 2. P. 836–845. doi: 10.1177/0300060518813742

[39] Zhang R, Zhang Z, Huang P, et al. Diagnostic performance of ultrasonography, dual-phase 99mTc-MIBI scintigraphy, early and delayed 99mTc-MIBI SPECT/CT in preoperative parathyroid gland localization in secondary hyperparathyroidism. BMC Med Imaging. 2020;20(1):91. doi: 10.1186/s12880-020-00490-3

[40] Zhang R., Zhang Z., Huang P., et al. Diagnostic performance of ultrasonography, dual-phase 99mTc-MIBI scintigraphy, early and delayed 99mTc-MIBI SPECT/CT in preoperative parathyroid gland localization in secondary hyperparathyroidism//BMC Med Imaging. 2020. Vol. 20, N 1. P. 91. doi: 10.1186/s12880-020-00490-3

[41] Treglia G, Sadeghi R, Schalin-Jäntti C, et al. Detection rate of 99m Tc-MIBI single photon emission computed tomography (SPECT)/CT in preoperative planning for patients with primary hyperparathyroidism: A meta-analysis. Head Neck. 2016;38(Suppl 1):2159–2172. doi: 10.1002/hed.24027

[42] Treglia G., Sadeghi R., Schalin-Jäntti C., et al. Detection rate of 99m Tc-MIBI single photon emission computed tomography (SPECT)/CT in preoperative planning for patients with primary hyperparathyroidism: A meta-analysis//Head Neck. 2016. Vol. 38, Suppl 1. P. 2159–2172. doi: 10.1002/hed.24027

[43] Huber GF, Hüllner M, Schmid C, et al. Benefit of 18F-fluorocholine PET imaging in parathyroid surgery. Eur Radiol. 2018;28(6):2700–2707. doi: 10.1007/s00330-017-5190-4

[44] Huber G.F., Hüllner M., Schmid C., et al. Benefit of 18F-fluorocholine PET imaging in parathyroid surgery//Eur Radiol. 2018. Vol. 28, N 6. P. 2700–2707. doi: 10.1007/s00330-017-5190-4

[45] Pacella CM, Mauri G. History of laser ablation. image-guided laser ablation. Springer, Cham; 2020. doi: 10.1007/978-3-030-21748-8_1

[46] Pacella C.M., Mauri G. History of laser ablation. Image-guided laser ablation. Springer, Cham. 2020. doi: 10.1007/978-3-030-21748-8_1

[47] Bown SG. Phototherapy in tumors. World J Surg. 1983;7(6):700–709. doi: 10.1007/BF01655209

[48] Bown S.G. Phototherapy in tumors//World J Surg. 1983. Vol. 7, N 6. P. 700–709. doi: 10.1007/BF01655209

[49] Appelbaum L, Goldberg SN, Ierace T, Mauri G. US-guided laser treatment of parathyroid adenomas. Int J Hyperthermia. 2020;37(1):366–372. doi: 10.1080/02656736.2020.1750712

[50] Appelbaum L., Goldberg S.N., Ierace T., Mauri G. US-guided laser treatment of parathyroid adenomas//Int J Hyperthermia. 2020. Vol. 37, N 1. P. 366–372. doi: 10.1080/02656736.2020.1750712

[51] Rhim H, Goldberg SN, Dodd GD, et al. Essential techniques for successful radio-frequency thermal ablation of malignant hepatic tumors. Radiographics. 2001;21:S17–S35. doi: 10.1148/radiographics.21.suppl_1.g01oc11s17

[52] Rhim H., Goldberg S.N., Dodd G.D., et al. Essential techniques for successful radio-frequency thermal ablation of malignant hepatic tumors//Radiographics. 2001. Vol. 21. P. 17–35. doi: 10.1148/radiographics.21.suppl_1.g01oc11s17

[53] McGahan JP, Dodd G. Radiofrequency ablation of the liver. American Journal of Roentgenology. 2001;176(1): 3–16 doi: 10.2214 / ajr.176.1.1760003

[54] McGahan J.P., Dodd G. Radiofrequency ablation of the liver//American Journal of Roentgenology. 2001. Vol. 176, N 1. P. 3–16. doi 10.2214 / ajr.176.1.1760003

[55] Hong K, Georgiades C. Radiofrequency ablation: mechanism of action and devices. J Vasc Interv Radiol. 2010;21(8 Suppl):179–186. doi: 10.1016/j.jvir.2010.04.008

[56] Hong K., Georgiades C. Radiofrequency ablation: mechanism of action and devices//J Vasc Interv Radiol. 2010. Vol. 21, Suppl 8. P. 179–186. doi: 10.1016/j.jvir.2010.04.008

[57] Zhang M, Tufano RP, Russell JO. Ultrasound-Guided radiofrequency ablation versus surgery for low-risk papillary thyroid microcarcinoma: results of over 5 years’ follow-up. Thyroid. 2020;30(3):408–417. doi: 10.1089/thy.2019.0147

[58] Zhang M., Tufano R.P., Russell J.O. Ultrasound-Guided radiofrequency ablation versus surgery for low-risk papillary thyroid microcarcinoma: results of over 5 years’ follow-up//Thyroid. 2020. Vol. 30, N 3. P. 408–417. doi: 10.1089/thy.2019.0147

[59] Schullian P, Johnston EW, Putzer D, et al. Safety and efficacy of stereotactic radiofrequency ablation for very large (≥8 cm) primary and metastatic liver tumors. Sci Rep. 2020;10(1):1618. doi: 10.1038/s41598-020-58383-y

[60] Schullian P., Johnston E.W., Putzer D., et al. Safety and efficacy of stereotactic radiofrequency ablation for very large (≥8 cm) primary and metastatic liver tumors//Sci Rep. 2020. Vol. 10, N 1. P. 1618. doi: 10.1038/s41598-020-58383-y

[61] Marshall HR, Shakeri S, Hosseiny M, et al. Long-term survival after percutaneous radiofrequency ablation of pathologically proven renal cell carcinoma in 100 patients. J Vasc Interv Radiol. 2020;31(1):15–24. doi: 10.1016/j.jvir.2019.09.011

[62] Marshall H.R., Shakeri S., Hosseiny M., et al. Long-Term survival after percutaneous radiofrequency ablation of pathologically proven renal cell carcinoma in 100 patients//J Vasc Interv Radiol. 2020. Vol. 31, N 1. P. 15–24. doi: 10.1016/j.jvir.2019.09.011

[63] Laird AM, Libutti SK. Minimally invasive parathyroidectomy versus bilateral neck exploration for primary hyperparathyroidism. Surg Oncol Clin N Am. 2016;25(1):103–118. doi: 10.1016/j.soc.2015.08.012

[64] Laird A.M., Libutti S.K. Minimally invasive parathyroidectomy versus bilateral neck exploration for primary hyperparathyroidism//Surg Oncol Clin N Am. 2016. Vol. 25, N 1. P. 103–118. doi: 10.1016/j.soc.2015.08.012

[65] Ha EJ, Baek JH, Baek SM. Minimally invasive treatment for benign parathyroid lesions: treatment efficacy and safety based on nodule characteristics. Korean J Radiol. 2020;21(12):1383–1392. doi: 10.3348/kjr.2020.0037

[66] Ha E.J., Baek J.H., Baek S.M. Minimally invasive treatment for benign parathyroid lesions: treatment efficacy and safety based on nodule characteristics//Korean J Radiol. 2020. Vol. 21, N 12. P. 1383–1392. doi: 10.3348/kjr.2020.0037

[67] Sidorov DV, Stepanov SO, Grishin NA, et al. Microwave ablation in the treatment of liver malignancies. Oncology. Journal named after P.A. Herzen. 2013;1(2):27–31. (In Russ).

[68] Сидоров Д.В., Степанов С.О., Гришин Н.А., и др. Микроволновая абляция при лечении злокачественных новообразований печени//Онкология. Журнал им. П.А. Герцена. 2013. Т. 1, № 2. С. 27–31.

[69] Lubner MG, Brace CL, Hinshaw JL, Lee FT. Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol. 2010;21(8):192–203 doi: 10.1016/j.jvir.2010.04.007

[70] Lubner M.G., Brace C.L., Hinshaw J.L., Lee F.T. Microwave tumor ablation: mechanism of action, clinical results, and devices//J Vasc Interv Radiol. 2010. Vol. 21, Suppl 8. P. 192–203. doi: 10.1016/j.jvir.2010.04.007

[71] Wei Y, Peng L, Li Y, et al. Clinical study on safety and efficacy of microwave ablation for primary hyperparathyroidism. Korean J Radiol. 2020;21(5):572–581. doi: 10.3348/kjr.2019.0593

[72] Wei Y., Peng L., Li Y., et al. Clinical study on safety and efficacy of microwave ablation for primary hyperparathyroidism//Korean J Radiol. 2020. Vol. 21, N 5. P. 572–581. doi: 10.3348/kjr.2019.0593

[73] Schlosser K, Bartsch DK, Diener MK, et al. Total parathyroidectomy with routine thymectomy and autotransplantation versus total parathyroidectomy alone for secondary hyperparathyroidism: results of a nonconfirmatory multicenter prospective randomized controlled pilot trial. Annals of Surgery. 2016;264(5):745–753. doi: 10.1097/SLA.0000000000001875

[74] Schlosser K., Bartsch D.K., Diener M.K., et al. Total parathyroidectomy with routine thymectomy and autotransplantation versus total parathyroidectomy alone for secondary hyperparathyroidism: results of a nonconfirmatory multicenter prospective randomized controlled pilot trial//Annals of Surgery. 2016. Vol. 264, N 5. P. 745–753. doi: 10.1097/SLA.0000000000001875

[75] Zhuo L, Zhang L, Peng LL, et al. Microwave ablation of hyperplastic parathyroid glands is a treatment option for end-stage renal disease patients ineligible for surgical resection. Int J Hyperthermia. 2019;36(1):29–35. doi: 10.1080/02656736.2018.1528392

[76] Zhuo L., Zhang L., Peng L.L., et al. Microwave ablation of hyperplastic parathyroid glands is a treatment option for end-stage renal disease patients ineligible for surgical resection//Int J Hyperthermia. 2019. Vol. 36, N 1. Р. 29–35. doi: 10.1080/02656736.2018.1528392

[77] Copelan A, Hartman J, Chehab M, Venkatesan AM. High-Intensity focused ultrasound: current status for image-guided therapy. Semin Intervent Radiol. 2015;32(4):398–415. doi: 10.1055/s-0035-1564793

[78] Copelan A., Hartman J., Chehab M., Venkatesan A.M. High-Intensity focused ultrasound: current status for image-guided therapy//Semin Intervent Radiol. 2015. Vol. 32, N 4. P. 398–415. doi: 10.1055/s-0035-1564793

[79] Suleimanov EA, Filonenko EV, Moskvicheva LI, et al. The possibility of hifu therapy at the present stage. Research and Practical Medicine Journal. 2016;3(3):76–82. (In Russ). doi: 10.17709/2409-2231-2016-3-3-8

[80] Suleimanov E.A., Filonenko E.V., Moskvicheva L.I., et al. The possibility of hifu therapy at the present stage//Research and Practical Medicine Journal. 2016. Vol. 3, N 3. P. 76–82. doi: 10.17709/2409-2231-2016-3-3-8

[81] Limani K, Aoun F, Holz S, et al. Single high intensity focused ultrasound session as a whole gland primary treatment for clinically localized prostate cancer: 10-year outcomes. Prostate Cancer. 2014;2014:186782. doi: 10.1155/2014/186782

[82] Limani K., Aoun F., Holz S., et al. Single high intensity focused ultrasound session as a whole gland primary treatment for clinically localized prostate cancer: 10-year outcomes//Prostate Cancer. 2014. Vol. 2014. Р. 186782. doi: 10.1155/2014/186782

[83] Chung SR, Baek JH, Suh CH, et al. Efficacy and safety of high-intensity focused ultrasound (HIFU) for treating benign thyroid nodules: a systematic review and meta-analysis. Acta Radiologica. 2020;61(12):1636–1643. doi: 10.1177/0284185120909339

[84] Chung S.R., Baek J.H., Suh C.H., et al. Efficacy and safety of high-intensity focused ultrasound (HIFU) for treating benign thyroid nodules: a systematic review and meta-analysis//Acta Radiologica. 2020. Vol. 61, N 12. P. 1636–1643. doi: 10.1177/0284185120909339

[85] Ploussard G. Re: Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: multi-institutional analysis of 418 patients. Eur Urol. 2018;73(1):140–141. doi: 10.1016/j.eururo.2017.09.031

[86] Ploussard G. Re: Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: multi-institutional analysis of 418 patients//Eur Urol. 2018. Vol. 73, N 1. P. 140–141. doi: 10.1016/j.eururo.2017.09.031

[87] Tsamatropoulos P, Valcavi R. HIFU and RFA Ablation for thyroid and parathyroid disease. Advanced thyroid and parathyroid ultrasound. Springer, Cham; 2017. doi: 10.1007/978-3-319-44100-9_36

[88] Tsamatropoulos P., Valcavi R. HIFU and RFA ablation for thyroid and parathyroid disease. Advanced thyroid and parathyroid ultrasound. Springer, Cham; 2017. doi: 10.1007/978-3-319-44100-9_36

[89] Kovatcheva R, Vlahov J, Stoinov J, et al. US-guided high-intensity focused ultrasound as a promising non-invasive method for treatment of primary hyperparathyroidism. Eur Radiol. 2014;24(9):2052–2058. doi: 10.1007/s00330-014-3252-4

[90] Kovatcheva R., Vlahov J., Stoinov J., et al. US-guided high-intensity focused ultrasound as a promising non-invasive method for treatment of primary hyperparathyroidism//Eur Radiol. 2014. Vol. 24, N 9. P. 2052–2058. doi: 10.1007/s00330-014-3252-4

[91] Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):179–184. doi: 10.1159/000339789

[92] Khwaja A. KDIGO clinical practice guidelines for acute kidney injury//Nephron Clin Pract. 2012. Vol. 120, N 4. Р. 179–184. doi: 10.1159/000339789

[93] Daugirdas JT, Depner TA, Inrig J, et al. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis. 2015;66(5):884–930. doi: 10.1053/j.ajkd.2015.07.015.

[94] Daugirdas J.T., Depner T.A., Inrig J., et al. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update//Am J Kidney Dis. 2015. Vol. 66, N 5. Р. 884–930. doi: 10.1053/j.ajkd.2015.07.015.

RIGHTS & PERMISSIONS

Rumiantsev P.O., Bubnov A.A., Degtyarev M.V., Slushchuk K.Y., Zakharova S.M., Agibalov D.Y., Timoshenko V.Y.